Literature DB >> 20424853

Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.

Masashi Shin1, Hayato Matsunaga, Kunio Fujiwara.   

Abstract

Although anthracycline antibiotics daunorubicin (DR), doxorubicin (DX), and epirubicin (ER) possess minor differences in their chemical structures, large differences are noted in their clinical use, as well as in cellular and plasma pharmacokinetic parameters in vivo. Immunocytochemistry for DR, DX, or ER was developed using an anti-DR monoclonal antibody (ADM-1-11), which has been demonstrated to react equally well with each of the three drugs, and therefore it was used for comparing their accumulation in several rat tissue cells after a single i.v. injection of each drug. In the kidney, immunoreactivity for each drug was distributed in essentially the same pattern and in the same strength 2 h after injection, but quite differently distributed in kidney cells thereafter, so that at 120-h post-injection significant amounts of DX and ER remained, but DR had almost completely vanished. Similar patterns of accumulation were observed in cells of other tissues including the pancreas, hair follicle, and stomach, with the exception of the intestine in which none of the three drugs remained after 120 h. These results appear to be supported by previous pharmacokinetic studies on the anthracyclines. The mechanism for such differences among the three drugs remains obscure, but the hydroxyl group at C-14 of DX and ER molecule might be related to the strong propensity of DX and ER to accumulate in tissue cells. The present results should contribute to the understanding of the mechanisms of the differences in the pharmacokinetics, as well as the possibly in anti-tumor activities of the anthracyclines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424853     DOI: 10.1007/s00418-010-0700-3

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  30 in total

1.  Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.

Authors:  S Ramanathan-Girish; M Boroujerdi
Journal:  J Pharm Pharmacol       Date:  2001-06       Impact factor: 3.765

2.  Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules.

Authors:  T P Schaub; J Kartenbeck; J König; O Vogel; R Witzgall; W Kriz; D Keppler
Journal:  J Am Soc Nephrol       Date:  1997-08       Impact factor: 10.121

3.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

4.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

Review 5.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

6.  The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique.

Authors:  R C Graham; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1966-04       Impact factor: 2.479

7.  Preliminary phase I study of 4'-epi-adriamycin.

Authors:  V Bonfante; G Bonadonna; F Villani; G Di Fronzo; A Martini; A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

8.  Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

Authors:  C M Camaggi; R Comparsi; E Strocchi; F Testoni; B Angelelli; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.

Authors:  A Martini; E Moro; M A Pacciarini; V Tamassia; N Natale; E Piazza
Journal:  Int J Clin Pharmacol Res       Date:  1984

10.  Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG).

Authors:  G J Quigley; A H Wang; G Ughetto; G van der Marel; J H van Boom; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  9 in total

1.  Immunocytochemistry for amoxicillin and its use for studying uptake of the drug in the intestine, liver, and kidney of rats.

Authors:  Kunio Fujiwara; Masashi Shin; Tsubasa Miyazaki; Yasuhiro Maruta
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 2.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

3.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

4.  A probable relationship between characteristic accumulation of doxorubicin and P-glycoprotein transporter in rat liver.

Authors:  Kunio Fujiwara; Masashi Shin; Tsubasa Miyazaki
Journal:  J Mol Histol       Date:  2011-08-06       Impact factor: 2.611

5.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

6.  Distribution study of peplomycin in rat kidney revealed by immunocytochemistry using monoclonal antibodies.

Authors:  Kunio Fujiwara; Masashi Shin; David M Hougaard; Tetsuya Saita
Journal:  Histochem Cell Biol       Date:  2010-12-14       Impact factor: 4.304

7.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Skeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin Chemotherapy.

Authors:  Sergio Fabris; David A MacLean
Journal:  PLoS One       Date:  2015-09-24       Impact factor: 3.240

9.  Accurate Monitoring of Renal Injury State through in Vivo Magnetic Resonance Imaging with Ferric Coordination Polymer Nanodots.

Authors:  Xiaodong Li; Hongda Chen; Fuyao Liu; Yixin Chen; Huimao Zhang; Zhenxin Wang
Journal:  ACS Omega       Date:  2018-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.